Medirom Healthcare faces Nasdaq delisting over late filing
Medirom Healthcare (NASDAQ:MRM) received a Nasdaq delisting notice for late filing of its annual report. The company requested a hearing, which temporarily halts trading suspension. It also faces a separate minimum bid price compliance issue. The company operates 281 wellness salons in Japan under the Re.Ra.Ku brand.
How this was made
The 30-second read
Why it matters
The notice sets a concrete suspension and delisting schedule unless the company’s Nasdaq Hearings Panel appeal results in a further stay. The company also faces an unresolved minimum bid price deficiency with a later compliance deadline.
Market read
Traders can reassess near-term liquidity and delisting probability for MRM based on the stated suspension/delisting date and the fact that the annual report filing does not cure the bid-price issue.
What to watch
The article notes the annual report was filed with the SEC, but it does not resolve the separate minimum bid price deficiency, which may keep the compliance overhang active even if the periodic reporting issue is cured.
Background
Nasdaq notified Medirom Healthcare of non-compliance for late filing of its 20-F for FY ended Dec. 31, 2025, after an extension was missed.
Ticker impact
Medirom Healthcare received a Nasdaq delisting notice after missing its 20-F filing deadline, with trading suspension and delisting set for Nov. 24 unless appealed.
Likely downward pressure as traders price in suspension/delisting risk and uncertainty around whether Nasdaq will grant further stays.
The article specifies Nasdaq’s non-compliance basis, the suspension/delisting date, and that the annual report filing does not cure the separate minimum bid price deficiency, leaving meaningful uncertainty.
Market effects
Highlights listing-compliance risk for small-cap foreign private issuers using ADS structures, potentially raising perceived credit/liquidity risk in similar names.
Limited direct impact beyond US-listed foreign issuers, but can affect cross-border investor sentiment toward Japan-based small caps.
Mostly company-specific; broader relevance is to exchange-rule enforcement and liquidity risk pricing for non-US issuers on Nasdaq.
Counterpoint
If Nasdaq grants an additional stay after the hearing and the company can address the minimum bid price issue, the delisting threat could be delayed, reducing downside tail risk.
Key entities
- companyMedirom Healthcare Technologies Inc.
NASDAQ-listed issuer facing Nasdaq delisting over late 20-F filing and an unresolved minimum bid price deficiency.
- regulatorNasdaq
Exchange that issued the delisting notice and set the suspension/delisting timeline, subject to appeal and hearings panel stay rules.

